Treatment with CD8+ tumor infiltrating lymphocytes did not improve response rate or survival in patients treated with IL-2 post-nephrectomy.[10] Although the results of adoptive immunotherapy are disappointing, with proper informed consent, more patients need to be enrolled into clinical trials. The gene discussed is IL2; the disease is neoplasm.